Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED
通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2666)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 24 JUNE 2026

At the annual general meeting (the "**AGM**") of Genertec Universal Medical Group Company Limited 通用環球醫療集團有限公司 (the "**Company**") held on 24 June 2026, all the proposed resolutions as set out in the notice of the AGM dated 2 June 2026 were duly passed by the shareholders of the Company by way of poll.

The poll results taken at the AGM are as follows:

Ordinary Resolutions		**Number of Votes (Approximate %)**	
		For	**Against**
1.	To receive and consider the audited consolidated financial statements of the Company and the reports of the directors of the Company (the "**Directors**") and auditors of the Company (the "**Auditors**") for the year ended 31 December 2025.	1,141,065,625 (99.95%)	610,000 (0.05%)
2.	To declare a final dividend of HK$0.36 per share for the year ended 31 December 2025.	1,141,652,625 (100.00%)	11,500 (0.00%)
3(a).	To re-elect Mr. Xia Qi as Director.	1,133,437,093 (99.28%)	8,227,032 (0.72%)
3(b).	To re-elect Mr. Tong Chaoyin as Director.	1,117,584,460 (97.89%)	24,079,665 (2.11%)
3(c).	To re-elect Mr. Huang Youjie as Director.	1,127,540,124 (98.76%)	14,123,991 (1.24%)
3(d).	To re-elect Mr. Ma Wanming as Director.	1,129,220,135 (98.91%)	12,443,990 (1.09%)
3(e).	To re-elect Mr. Li Yinquan as Director.	1,095,218,665 (95.93%)	46,445,460 (4.07%)

4.	To authorise the board of Directors (the "**Board**") to fix the Directors' remuneration.	1,140,642,820 (99.91%)	1,021,305 (0.09%)
5.	To re-appoint SHINEWING (HK) CPA LIMITED as the Auditor and to authorise the Board to fix their remuneration.	1,141,632,771 (100.00%)	31,354 (0.00%)
6.	To grant a general mandate to the Directors to buy back shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding treasury shares, if any) as at the date of passing of this resolution.	1,141,633,771 (100.00%)	30,354 (0.00%)
7.	To grant a general mandate to the Directors to issue, allot and deal with additional shares of the Company (including any sale or transfer of treasury shares) not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares, if any) as at the date of passing of this resolution.	1,026,328,707 (89.90%)	115,335,418 (10.10%)
8.	To extend the general mandate granted to the Directors to issue, allot and deal with additional shares in the capital of the Company by adding the aggregate number of the shares bought back by the Company.	1,032,294,113 (90.42%)	109,370,012 (9.58%)
9.	To consider and approve the revised annual cap for the year ending 31 December 2026 under the Medical Related Product Procurement Framework Agreement (as defined in the circular of the Company dated 2 June 2026 (the "**Circular**")).	494,172,925 (100.00%)	12,500 (0.00%)
Special Resolution		**Number of Votes (Approximate %)**	
		For	**Against**
10.	To amend the articles of association of the Company.	1,117,577,207 (97.89%)	24,085,418 (2.11%)

As stated in the Circular, China General Technology (Group) Holding Company Limited ("**GT-PRC**") is the controlling shareholder holding approximately 37.66% of the total issued share capital of the

Company (i.e., 758,462,200 shares) through (i) its direct wholly-owned subsidiary, Genertec Hong Kong International Capital Limited (694,983,895 Shares, representing approximately 34.50% of the Company's total issued share capital); and (ii) its indirect wholly-owned subsidiary, China General Consulting & Investment (Hong Kong) Co., Limited (63,478,305 Shares, representing approximately 3.15% of the Company's total issued share capital). As such, Genertec Hong Kong International Capital Limited and China General Consulting & Investment (Hong Kong) Co., Limited shall abstain and had abstained from voting on the ordinary resolution approving the revised annual cap for the year ending 31 December 2026 under the Medical Related Product Procurement Framework Agreement at the AGM. Genertec Hong Kong International Capital Limited and China General Consulting & Investment (Hong Kong) Co., Limited were entitled to vote on the other resolutions at the AGM.

As at the date of the AGM, the total number of shares of the Company in issue was 2,014,204,924 shares, Accordingly, the total number of shares entitling the holders thereof to attend and vote on approving the revised annual cap for the year ending 31 December 2026 under the Medical Related Product Procurement Framework Agreement at the AGM was 1,255,742,724, and the total number of shares entitling the holders thereof to attend and vote on the other resolutions at the AGM was 2,014,204,924.

Saved as disclosed above, there were no shares entitling the holders to attend and abstain from voting on the resolutions at the AGM.

Mr. Chen Shisu, Mr. Xia Qi and Ms. Wang Lin, being the executive Directors, Mr. Lin Chunhai, Mr. Huang Youjie and Mr. Ma Wanming, being the non-executive Directors and Mr. Chow Siu Lui, being an independent non-executive Director attended the AGM in person. Mr. Tong Chaoyin, being a non-executive Director and Mr. Li Yinquan, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas, being the independent non-executive Directors, attended the AGM by way of video conference.

The Company's share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM.

For and on behalf of the Board
Genertec Universal Medical Group Company Limited
通用環球醫療集團有限公司
Chen Shisu
Chairman of the Board

Hong Kong, 24 June 2026

As at the date of this announcement, the executive Directors are Mr. Chen Shisu (Chairman), Mr. Xia Qi and Ms. Wang Lin; the non-executive Directors are Mr. Tong Chaoyin, Mr. Lin Chunhai, Mr. Huang Youjie and Mr. Ma Wanming; and the independent non-executive Directors are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.